08.05.2023 • NewsPCASDICSeqens

PCAS in Exclusive Talks for Sale of Canada Business to Japan’s DIC

PCAS, a French specialist in complex molecules for the life sciences and specialty chemicals markets, has received an offer for its Canadian subsidiary from Japanese chemicals company DIC.

© Getty Images/iStockphoto
© Getty Images/iStockphoto

The two companies have now entered into exclusive negotiations — DIC’s offer values PCAS Canada at €88.2 million. A final decision would remain subject to authorization from PCAS’ supervisory board and majority shareholder Seqens, along with other conditions, PCAS said.

PCAS Canada specializes in the synthesis, development and custom manufacture of ingredients used in the formulation of light-sensitive resins, anti-reflective products for microelectronics or as semiconductors for the printed electronics industry. The company also manufactures organic molecules used in pharmaceutical production.

Author: Elaine Burridge, Freelance Journalist

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.